Please scroll down to see this session’s presentations. At the session's scheduled start time, click on the presentation title to view each video.

COVID-19

One-Hour Concurrent Session

A Closer Look at Coagulopathy in COVID-19 Patients

Monday, April 18, 2022

2:00 PM – 3:00 PM US CST

CE: 0.75

Concurrent Session Moderator(s)

MB

Marilyn Bulloch, PharmD, BCPS, FCCM

Dept of Pharmacy Practice
Auburn University Harrison School of Pharmacy
Kimberly, Alabama

Speaker's Bureau - Xofluza

COVID-19 has been shown to infect endothelial cells, which, along with inflammation, can lead to a hypercoagulable state. This session will review the pathophysiology of endotheliopathy and perturbation of coagulation in COVID-19, screening strategies for deep vein thrombosis and pulmonary embolism, evidence about timing and dosing of prophylactic and therapeutic anticoagulation, evidence for hyperviscosity, and the role of cytokine release in altered coagulation. Lessons learned from the COVID-19 pandemic may be applicable to other critically ill patients.

Learning Objectives:

Formulate diagnostic strategies for coagulation status in patients with COVID-19 and other critically ill patients
Construct evidence-based algorithms for anticoagulaton, both prophylactic and therapeutic, in critically ill patients
Recognize hypercoagulability and explore treatments
Explore the role of cytokines and inflammation in mediating coagulopathy and interpret levels of biomarkers of inflammation in this context

Presentations:

COVID-19 Hypercoagulability: Lessons Learned
Concurrent Session Faculty: Marilyn Bulloch, PharmD, BCPS, FCCM – Auburn University Harrison School of Pharmacy
COVID-19 Hypercoagulability: Pathophysiology
Concurrent Session Faculty: Mark Caridi-Scheible, MD – Emory University Hospital
Hyperviscosity
Concurrent Session Faculty: Nicholas A. Barker, BCCCP, PharmD, RPh – Emory Saint Joseph's Hospital